Argenx presents new Efgartigimod data at EULAR 2025
argenx (ARGX) SE 'announced the presentation of positive results from Phase 2 studies evaluating VYVGART in Sjogren's disease and idiopathic inflammatory myopathies at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the FDA has granted efgartigimod Fast Track designation for the treatment of primary Sjogren's disease.'
Confident Investing Starts Here:
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Spark Biomedical Completes Enrollment in a Neurostimulation Pivotal Trial for Opioid Use Disorder
Final enrollment concludes for Spark Biomedical's pivotal study investigating a non-invasive, drug-free neurostimulation therapy aimed at improving treatment retention for adults with opioid use disorder. Dallas, TX, June 12, 2025 (GLOBE NEWSWIRE) -- Spark Biomedical, a leader in wearable neurostimulation technology, has completed enrollment for its pivotal clinical trial, which aims to improve treatment retention for adults with opioid use disorder. Funded by the National Institute on Drug Abuse (NIDA) under the HEAL Initiative, the trial was conducted in partnership with the Hazelden Betty Ford Foundation and Gaudenzia. With relapse rates exceeding 70% among individuals with opioid use disorder and synthetic opioids like fentanyl driving overdose deaths to record highs, the need for innovative interventions has never been greater. Spark Biomedical's study investigated the use of wearable transcutaneous auricular neurostimulation (tAN® therapy) as a novel method to improve acute and long-term recovery. Additionally, the study examined the potential synergistic effects of tAN and two other approved medications for opioid use disorder (MOUD), lofexidine and XR-naltrexone. By helping individuals stay engaged in treatment longer, the trial seeks to support lasting recovery without additional opioid-based medications. Spark Biomedical's Co-founder & Chief Science Officer, Dr. Navid Khodaparast, Ph.D., shared, 'Completing enrollment marks a critical milestone in advancing transcutaneous auricular neurostimulation as a non-invasive, drug-free therapy for opioid use disorder. This study not only evaluates the standalone efficacy of wearable neurostimulation in enhancing treatment retention but also explores its potential to synergize with established pharmacotherapies.' Leaders from both partner institutions emphasized the importance of the study's potential: 'At Hazelden Betty Ford, we are committed to advancing science-based, compassionate care for those affected by opioid use disorder,' said Alta DeRoo, M.D., Chief Medical Officer, Hazelden Betty Ford Foundation. 'This pivotal trial represents non-pharmaceutical options to treat opioid withdrawal. In addition to FDA-approved medications for opioid use disorder, this non-pharmaceutical option will empower patients in their treatment options. This provides us with more weapons and a hopeful step forward in combatting one of the most urgent public health challenges of our time.' "This trial represents more than a data point—it's a breakthrough in how we think about sustaining engagement in treatment for opioid use disorder,' said Dr. Bhavani Raghavan Lobo, Psy.D., Chief Research Officer, Gaudenzia. 'We were honored to lead enrollment and completion efforts, and we're incredibly proud that so many participants entrusted us with their care. These results are a testament to our team's clinical excellence and compassion, and they reinforce the importance of investing in non-invasive, science-driven solutions to address the nation's overdose crisis.' Results from this research will contribute to an anticipated FDA submission and mark a significant milestone in the advancement of drug-free solutions for opioid use disorder. About Gaudenzia Gaudenzia, Inc. is one of the largest nonprofit providers of treatment for people with substance use and co-occurring disorders in the United States, with 51 facilities operating in Pennsylvania, Maryland, Delaware, and Washington, D.C. The agency serves about 15,000 individuals annually and operates 120 programs providing a full continuum of care. Since 1968, Gaudenzia has provided specialized services and programs for all demographics, including pregnant and parenting women, adolescents, people with substance use and co-occurring disorders, and more. Those seeking help can call Gaudenzia's Treatment and Referral HelpLine at 833-976-HELP (4357). For more information, visit About the Hazelden Betty Ford Foundation Harnessing science, love and the wisdom of lived experience, the Hazelden Betty Ford Foundation is a force of healing and hope for individuals, families and communities affected by substance use and mental health conditions. As the nation's foremost nonprofit provider of comprehensive behavioral health care, the Foundation leads the way in helping society rise above stigma and overcome addiction. With a legacy that began in 1949 and includes the 1982 founding of the Betty Ford Center, the Foundation now has treatment centers and telehealth services nationwide as well as a network of collaborators throughout health care. Charitable support and a commitment to innovation drive ongoing advances in care, research, programs and services to impact more lives. In addition to clinical care, Hazelden Betty Ford encompasses a graduate school, a publishing division, a research center, thought leadership and advocacy, professional and medical education programs, school-based prevention resources and a specialized program for children—with a commitment to diversity, equity and inclusion in all of its endeavors. Learn more at About Spark Biomedical Spark Biomedical, Inc. Is a leading U.S.-based medical device developer, committed to unlocking the potential of bioelectronic medicine and bringing to market novel wearable neurostimulation treatment options in behavioral health, women's health, hemostasis, pediatrics, and chronic pain. Spark leverages its neuroscience and engineering expertise to empower healthcare providers and researchers with innovative, evidence-based tools designed to address complex care situations which exceed the capabilities of existing treatment options. Spark has received funding from federal institutions, such as the NIH and DoD, and continues to partner with private and academic institutions. Spark Biomedical is empowering a better way forward for the future of patient care and medical technology. For more information, visit For more information, please contact Udim Obot at ### CONTACT: Udim Obot Spark Biomedical 844-654-7775
Yahoo
17 minutes ago
- Yahoo
Pluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development Timelines
SEATTLE, June 12, 2025--(BUSINESS WIRE)--Pluristyx, a leading provider of tools and services for cell product development, today announced the launch of their first-of-its-kind PluriForm™ Organoid Kit, a turnkey solution to eliminate critical bottlenecks in organoid research and allow scientists to rapidly and reliably make pluripotent aggregates using quality-assured, induced pluripotent stem cells (iPSCs). The kit saves weeks of cell culture work and eliminates variability in organoid manufacturing, allowing reproducible and iterative development and application of organoids. Organoids are three-dimensional cellular models that recapitulate key aspects of organ function. They are used in safety and toxicology screening, drug discovery, disease modeling, and personalized medicine and could replace many instances where animal testing is required. However, organoid use has been hindered by lengthy and highly variable processes to make iPSC aggregates. The PluriForm Organoid Kit solves this challenge by providing a ready-to-use system that includes cryopreserved, Ready-to-Differentiate® (RTD®), suspension-adapted iPSCs and optimized media with a simple protocol. Each kit contains a vial of 25 million cells and all necessary reagents. Within minutes, the end-user can combine the components and generate thousands of uniform aggregates in just one day. These pluripotent aggregates display consistent morphology and size distribution, critical parameters for reproducible differentiation to a wide range of organoids, including neuronal, liver, intestinal, pancreatic, kidney, and cardiac models. "Our goal is to accelerate the pace of discovery in the pharmaceutical and biotech industries," said Dr. Benjamin Fryer, Co-founder and CEO of Pluristyx. "With PluriForm, we have addressed consistent feedback that the initial step of creating reproducible cell aggregates is a major source of delay and inconsistency in organoid workflows." The FDA's Roadmap to Reduced Animal Testing in Preclinical Safety Studies, released in April 2025, explicitly advocates use of organoids to replace animal models. The PluriForm™ Organoid Kit is essential to enabling and accelerating the transition away from use of animals and other less-than-optimal cell assays and is now available for purchase through Pluristyx direct sales channels. About Pluristyx Pluristyx enables the development of next-generation therapies and technologies through a portfolio of cutting-edge products and services for the regenerative medicine industry. With a focus on quality, consistency, and scalability, Pluristyx empowers scientists to bring their most innovative concepts from the lab to the clinic. Pluristyx: Tomorrow's Cell Therapies, Today®. View source version on Contacts Media Contact Dr. Priya BaraniakChief Commercial and Development Officerpriya@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
19 minutes ago
- Business Upturn
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
Geneva, Switzerland & Waltham, Mass., United States: FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA's decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity. Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world's countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use. About Uncomplicated Gonorrhea With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences. With the rise and spread of drug-resistant infections, the World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the ten most critical global threats to public health. The bacterium Neisseria gonorrhoeae, which causes gonorrhea, has progressively developed resistance to most classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984. About Zoliflodacin Zoliflodacin is an investigational first-in-class antibacterial that is administered in a single oral dose for the treatment of uncomplicated gonorrhea. The oral route of administration simplifies treatment by providing a convenient option for patients unable to receive an intramuscular injection. Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In in vitro studies, zoliflodacin demonstrated activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. In a pivotal Phase 3 clinical trial, zoliflodacin demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection with a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of 500mg ceftriaxone followed by 1g of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial. About GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ('IST'), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ('GSK'). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva also markets ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva, go to . For information about Innoviva Specialty Therapeutics, go to . ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA® is a trademark of Basilea Pharmaceutica Ltd, Allschwil. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
